06 November 2020
Europe’s drug regulator will not set a minimum level of efficacy for potential COVID-19 vaccines when considering them for approval, it said on Wednesday (November 04), taking a different approach to that of its U.S. counterpart.
Human studies need to demonstrate a convincing level of efficacy, but whether a shot would be considered acceptable for approval will be assessed case by case based on all available data on its safety and efficacy, the European Medicines Agency (EMA) said in an email.
“Therefore it is not possible to specifically quantify in advance the minimum level of efficacy for a vaccine to be considered acceptable for approval,” it said.
The U.S. Food and Drug Administration has said vaccines must demonstrate at least 50% efficacy – meaning at least twice as many infections among volunteers who got a placebo as among those in the vaccine group.
The EMA is reviewing candidate vaccines by drug makers Pfizer, AstraZeneca and Moderna under a real-time release process, in an effort to speed up the approval if trials of any of those vaccines are successful. They are undergoing late-stage trials.
The EMA said, that its human medicines committee (CHMP) is drawing up guidance on its requirements for COVID-19 vaccine approval and will publish the information as soon as it is ready.
Print2021 in Focus: Pharm Exec’s Annual Industry Outlook
15 January 2021
Research Eye stem cell transplant to treat blindness bolsters retinal function in monkeys
15 January 2021
Harnessing the power of a digital assistant to accelerate patient access
14 January 2021
A COVID-19 treatment candidate that fuses tiny antibodies from llamas and alpacas shows promise
14 January 2021